Cited by 323Proteoglycans and glycosaminoglycans researchIntramuscular injections and effectsHydrogels: synthesis, properties, applications

The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.

Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration

Frost, Gregory I·2007·Expert Opinion on Drug Delivery

DOI 10.1517/17425247.4.4.427

Open this paper in CoChat — free account

Abstract

The extracellular matrix is a significant barrier to the effective subcutaneous delivery of many drugs, limiting both pharmacokinetic parameters and injection volumes. The space outside adipocytes in the hypodermis is not a fluid, but rather a solid extracellular matrix of collageneous fibrils embedded within a glycosaminoglycan-rich viscoelastic gel that buffers convective forces. The extracellular matrix limits the volume of drug that can be injected at a single site, as well as the rate and amount that reach the vascular compartment. A fully human recombinant DNA-derived hyaluronidase enzyme (rHuPH20) has been developed to leverage the historical efficacy of animal testes extract-derived spreading factors to reversibly modify the hypodermis, in light of discovery of the human hyaluronidase gene family. The application of this technology to increase both injection volumes and bioavailability from subcutaneous injection may overcome some key limitations of this route of administration in multiple settings of care.

Integrity signals

Registry

Crossref · 10.1517/17425247.4.4.427

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

On the Absorption of Fluids from the Connective Tissue Spaces
Starling, E. H. (1896) · The Journal of Physiology · doi:10.1113/jphysiol.1896.sp000596 · Cited by 2,126
Cell Biology of Extracellular Matrix
Hay, E. D. (1988) · Springer eBooks · doi:10.1007/978-1-4613-0881-2 · Cited by 1,470
Effect of Collagen Turnover on the Accumulation of Advanced Glycation End Products
Verzijl, N., DeGroot, J., Thorpe, S. R., Bank, R. A., Shaw, J., Lyons, T. J., Bijlsma, J. W. J., Lafeber, F. P. J. G., Baynes, J., & TeKoppele, J. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m006700200 · Cited by 979
Interstitial-lymphatic mechanisms in the control of extracellular fluid volume
Aukland, K., & Reed, R. K. (1993) · Physiological Reviews · doi:10.1152/physrev.1993.73.1.1 · Cited by 938
The six hyaluronidase-like genes in the human and mouse genomes
Csoka, A. B., Frost, G. I., & Stern, R. (2001) · Matrix Biology · doi:10.1016/s0945-053x(01)00172-x · Cited by 590
Self-citation
Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)
Lundin, J., Kimby, E., Björkholm, M., Broliden, P.-A., Celsing, F., Hjalmar, V., Möllgård, L., Rebello, P., Hale, G., Waldmann, H., et al. (2002) · Blood · doi:10.1182/blood-2002-01-0159 · Cited by 497
Effect of Molecular Weight on the Lymphatic Absorption of Water-Soluble Compounds Following Subcutaneous Administration
Supersaxo, A., Hein, W. R., & Steffen, H. (1990) · Pharmaceutical Research · doi:10.1023/a:1015880819328 · Cited by 386
A recombinant human enzyme for enhanced interstitial transport of therapeutics
Bookbinder, L. H., Hofer, A., Haller, M. F., Zepeda, M. L., Keller, G.-A., Lim, J. E., Edgington, T. S., Shepard, H. M., Patton, J. S., & Frost, G. I. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.05.027 · Cited by 282
Self-citation
Purification, Cloning, and Expression of Human Plasma Hyaluronidase
Frost, G. I., Csóka, T. B., Wong, T., & Stern, R. S. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6773 · Cited by 236
Self-citation
Bee venom hyaluronidase is homologous to a membrane protein of mammalian sperm.
Gmachl, M., & Kreil, G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3569 · Cited by 206

Show all 66 references

Research works printed but not linked: 18

TAYLOR, 1984, Am. Physiol. Soc., 4, 467
REED, 1989, Am. J. Physiol., 257, 1819
FRASER, 1989, Ciba Found. Symp., 143, 41
MCMINN RMH (Ed.), Last's Anatomy: Regional and applied (9th Edition). London: Churchill Livingstone (1994).
10.1113/expphysiol.1991.sp003536 · DOI
DURAN, 1928, Comptes Rendus Hebdomadaires de Séances et Mémoires de la Société de Biologie, 99, 6
DUTHIE, 1939, Nature, 977
MEYER K, Hyaluronidases, In : BOYER PD (Ed.), The Enzymes. Academic Press, New York, (1971):307-320.
MEYER, 1952, Adv. Enzymol. Relat. Subj. Biochem., 13, 199
MEYER K, HOFFMAN P, LINKER A: HYALURONIDASES. In: BOYER PD, LARDY H, MYRBÄCK K (Eds), The Enzymes, 2nd Edition, Volume 4, Academic Press, New York (1960):447-460.
HYUGA, 1993, Int. J. Dev. Biol., 37, 319
LINSENMAYER, 1981, Plenum, 5
WOLF, 1982, J. Pharmacol. Exp. Ther., 222, 331
JAWORSKI, 1950, Am. J. Dis. Child., 79, 59
ALWITRY, 2002, J. Cataract Refract. Surg., 8, 11420
1998, J. Intravenous Nursing, 21, S36
RASZKA, 1990, J. Perinatol., 10, 146
SIMON, 1949, Amer. J. Roentgen., 61, 91

Sorted by citations

The evolution of commercial drug delivery technologies
Vargason, A. M., Anselmo, A. C., & Mitragotri, S. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00698-w · Cited by 1,361
Non-invasive delivery strategies for biologics
Anselmo, A. C., Gokarn, Y. R., & Mitragotri, S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.183 · Cited by 671
Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities
Bittner, B., Richter, W., & Schmidt, J. (2018) · BioDrugs · doi:10.1007/s40259-018-0295-0 · Cited by 447
Mechanistic Determinants of Biotherapeutics Absorption Following SC Administration
Richter, W. F., Bhansali, S. G., & Morris, M. E. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9367-0 · Cited by 377
Hyaluronan-CD44 Interactions in Cancer: Paradoxes and Possibilities
Toole, B. P. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0479 · Cited by 370
Extracellular vesicles as a platform for membrane‐associated therapeutic protein delivery
Yang, Y., Hong, Y., Cho, E., Kim, G. B., & Kim, I. (2018) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2018.1440131 · Cited by 266
Subcutaneous delivery of monoclonal antibodies: How do we get there?
Viola, M., Sequeira, J. A. D., Seiça, R. M. F., Veiga, F., Serra, J. P., Paiva‐Santos, A. C., & Ribeiro, A. J. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.08.001 · Cited by 247
Subcutaneous Absorption of Biotherapeutics: Knowns and Unknowns
Richter, W. F., & Jacobsen, B. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.059238 · Cited by 235
Ocular delivery of proteins and peptides: Challenges and novel formulation approaches
Mandal, A., Pal, D., Agrahari, V., Trinh, H. M., Joseph, M. A., & Mitra, A. K. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.01.008 · Cited by 232
High-concentration protein formulations: How high is high?
Garidel, P., Kuhn, A. B., Schäfer, L. V., Karow-Zwick, A. R., & Blech, M. (2017) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2017.06.029 · Cited by 187
Home-Based Subcutaneous Immunoglobulin Versus Hospital-Based Intravenous Immunoglobulin in Treatment of Primary Antibody Deficiencies: Systematic Review and Meta Analysis
Abolhassani, H., Sadaghiani, M. S., Aghamohammadi, A., Ochs, H. D., & Rezaei, N. (2012) · Journal of Clinical Immunology · doi:10.1007/s10875-012-9720-1 · Cited by 185
Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease
Jolles, S. R. A., Orange, J. S., Gardulf, A., Stein, M. R., Shapiro, R., Borte, M., & Berger, M. R. (2014) · Clinical & Experimental Immunology · doi:10.1111/cei.12485 · Cited by 180
Fast-acting insulin aspart improves glycemic control in basal-bolus treatment for type 1 diabetes: Results of a 26-week multicenter, active-controlled, treat-to-target, randomized, parallel-group trial (ONSET 1)
Russell-Jones, D., Bode, B. W., De Block, C., Franek, E., Heller, S. R., Mathieu, C., Philis-Tsimikas, A., Rose, L., Woo, V. C., Østerskov, A. B., et al. (2017) · Diabetes Care · doi:10.2337/dc16-1771 · Cited by 177
ENHANZE ® drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20
Locke, K. W., Maneval, D. C., & LaBarre, M. J. (2019) · Drug Delivery · doi:10.1080/10717544.2018.1551442 · Cited by 177
Intradermal delivery of vaccine nanoparticles using hollow microneedle array generates enhanced and balanced immune response
Niu, L., Chu, L. Y., Burton, S. A., Hansen, K. J., & Panyam, J. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.12.026 · Cited by 177
Subcutaneous Injection Volume of Biopharmaceuticals—Pushing the Boundaries
Mathaes, R., Koulov, A. V., Joerg, S., & Mahler, H. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2016.05.029 · Cited by 179
Parenteral protein formulations: An overview of approved products within the European Union
Gervasi, V., Agnol, R. D., Cullen, S., McCoy, T. R., Vučen, S. R., & Crean, A. M. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.07.011 · Cited by 169
Improving the outcomes of biopharmaceutical delivery via the subcutaneous route by understanding the chemical, physical and physiological properties of the subcutaneous injection site
Kinnunen, H. M., & Mrsny, R. J. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.011 · Cited by 164
Predicting bioavailability of monoclonal antibodies after subcutaneous administration: Open innovation challenge
Sánchez-Félix, M., Burke, M. D., Chen, H. H., Patterson, C. M., & Mittal, S. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.009 · Cited by 164
Infusion pressure and pain during microneedle injection into skin of human subjects
Gupta, J., Park, S. S., Bondy, B. J., Felner, E. I., & Prausnitz, M. R. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.05.061 · Cited by 157
HALO-109–301: a Phase III trial of PEGPH20 (with Pemcitabine and Nab-Paclitaxel) in Hyaluronic Acid-High Stage IV Pancreatic Cancer
Doherty, G. J., Tempero, M. A., & Corrie, P. G. (2017) · Future Oncology · doi:10.2217/fon-2017-0338 · Cited by 157
Overview of Antibody Drug Delivery
Awwad, S., & Angkawinitwong, U. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10030083 · Cited by 159
Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency
Wasserman, R. L., Melamed, I., Stein, M. R., Gupta, S., Puck, J. M., Engl, W., Leibl, H., McCoy, B., Empson, V. G., Gelmont, D. M., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.06.021 · Cited by 151
Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration
Zheng, Y., Tesar, D. B., Benincosa, L., Birnböck, H., Boswell, C. A., Bumbaca, D., Cowan, K. J., Danilenko, D. M., Daugherty, A. L., Fielder, P. J., et al. (2012) · mAbs · doi:10.4161/mabs.4.2.19387 · Cited by 149
Subcutaneous immunoglobulin: opportunities and outlook
Misbah, S., Sturzenegger, M., Borte, M., Shapiro, R. S., Wasserman, R. L., Berger, M., & Ochs, H. D. (2009) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2009.04027.x · Cited by 139
Defective lung function following influenza virus is due to prolonged, reversible hyaluronan synthesis
Bell, T. J., Brand, O. J., Morgan, D. J., Salek‐Ardakani, S., Jagger, C. P., Fujimori, T., Cholewa, L., Tilakaratna, V., Östling, J., Thomas, M., et al. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.06.006 · Cited by 134
Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?
Deng, R., Jin, F., Prabhu, S., & Iyer, S. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.643868 · Cited by 126
Subcutaneous Delivery of High-Dose/Volume Biologics: Current Status and Prospect for Future Advancements
Badkar, A. V., Gandhi, R. B., Davis, S. P., & LaBarre, M. J. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s287323 · Cited by 133
Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial
Davies, A., Merli, F., Mihaljević, B., Mercadal, S., Siritanaratkul, N., Solal-Céligny, P., Boehnke, A., Berge, C., Genevray, M., Zharkov, A., et al. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30078-9 · Cited by 125
Hyaluronidase: a review of approved formulations, indications and off-label use in chronic pain management
Dunn, A. L., Heavner, J. E., Racz, G. B., & Day, M. R. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903490382 · Cited by 123
Clinical Applications of Hyaluronidase
Weber, G. C., Buhren, B. A., Schrumpf, H., Wohlrab, J., & Gerber, P. A. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-7709-9_12 · Cited by 115
Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study
Davies, A., Merli, F., Mihaljevic, B., Siritanaratkul, N., Solal-Céligny, P., Barrett, M., Berge, C., Bittner, B., Boehnke, A., McIntyre, C., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70005-1 · Cited by 114
Accelerating the development of novel technologies and tools for the subcutaneous delivery of biotherapeutics
Collins, D. S., Sánchez-Félix, M., Badkar, A. V., & Mrsny, R. J. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.02.036 · Cited by 113
Subcutaneous Administration of IgG
Berger, M. (2008) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2008.07.002 · Cited by 113
A Bottom-Up Whole-Body Physiologically Based Pharmacokinetic Model to Mechanistically Predict Tissue Distribution and the Rate of Subcutaneous Absorption of Therapeutic Proteins
Gill, K. L., Gardner, I. B., Li, L., & Jamei, M. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9819-4 · Cited by 109
A systematic review of commercial high concentration antibody drug products approved in the US: formulation composition, dosage form design and primary packaging considerations
Ghosh, I., Gutka, H. J., Krause, M. E., Clemens, R., & Kashi, R. S. (2023) · mAbs · doi:10.1080/19420862.2023.2205540 · Cited by 108
Therapeutic Targeting of Hyaluronan in the Tumor Stroma
Kultti, A. H., Li, X., Jiang, P., Thompson, C. B., Frost, G. I., & Shepard, H. M. (2012) · Cancers · doi:10.3390/cancers4030873 · Cited by 107
Self-citation
Immunogenicity Challenges Associated with Subcutaneous Delivery of Therapeutic Proteins
Jarvi, N. L., & Balu‐Iyer, S. V. (2021) · BioDrugs · doi:10.1007/s40259-020-00465-4 · Cited by 105
Drug Development of Therapeutic Monoclonal Antibodies
Mould, D. R., & Meibohm, B. (2016) · BioDrugs · doi:10.1007/s40259-016-0181-6 · Cited by 101
Comparison of Subcutaneous Versus Intravenous Administration of Rituximab As Maintenance Treatment for Follicular Lymphoma: Results From a Two-Stage, Phase IB Study
Salar, A., Avivi, I. M., Bittner, B., Bouabdallah, R., Brewster, M., Catalani, O., Follows, G., Haynes, A., Hourcade‐Potelleret, F., Janíková, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.2631 · Cited by 99
Monoclonal antibodies: formulations of marketed products and recent advances in novel delivery system
Cui, Y., Cui, P., Chen, B., Li, S., & Guan, H. (2017) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2017.1278768 · Cited by 96
Pharmacokinetic Modeling of the Subcutaneous Absorption of Therapeutic Proteins
Kagan, L. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.059121 · Cited by 92
Progress in Gammaglobulin Therapy for Immunodeficiency: From Subcutaneous to Intravenous Infusions and Back Again
Wasserman, R. L. (2012) · Journal of Clinical Immunology · doi:10.1007/s10875-012-9740-x · Cited by 92
Perspectives on Subcutaneous Route of Administration as an Immunogenicity Risk Factor for Therapeutic Proteins
Hamuro, L., Kijanka, G., Kinderman, F. S., Kropshofer, H., Bu, D., Zepeda, M. L., & Jawa, V. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2017.05.030 · Cited by 94
Subcutaneous Administration of Monoclonal Antibodies in Oncology
Jackisch, C., Müller, V., Maintz, C., Hell, S., & Ataseven, B. (2014) · Geburtshilfe und Frauenheilkunde · doi:10.1055/s-0034-1368173 · Cited by 90
Localized co-delivery of collagenase and trastuzumab by thermosensitive hydrogels for enhanced antitumor efficacy in human breast xenograft
Pan, A., Wang, Z., Chen, B., Dai, W., Zhang, H., He, B., Wang, X., Wang, Y., & Zhang, Q. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1474971 · Cited by 85
Microneedle-mediated vaccine delivery: Harnessing cutaneous immunobiology to improve efficacy
Al-Zahrani, S., Zaric, M., McCrudden, C. M., Scott, C., Kissenpfennig, A., & Donnelly, R. F. (2012) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2012.676038 · Cited by 84
Subcutaneous Infusion of Fluids for Hydration or Nutrition: A Review
Caccialanza, R., Constans, T., Cotogni, P., Zaloga, G. P., & Pontes‐Arruda, A. (2016) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607116676593 · Cited by 79
Recombinant Human Hyaluronidase-Facilitated Subcutaneous Immunoglobulin Infusion in Primary Immunodeficiency Diseases
Wasserman, R. L. (2017) · Immunotherapy · doi:10.2217/imt-2017-0092 · Cited by 77
Subcutaneous Drug Delivery
Dychter, S. S., Gold, D. A., & Haller, M. F. (2012) · Journal of Infusion Nursing · doi:10.1097/nan.0b013e31824d2271 · Cited by 76
Safety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administration in adult volunteers
Harb, G., Lebel, F. M., Battikha, J. P., & Thackara, J. W. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903432900 · Cited by 74
Development of glucose-responsive ‘smart’ insulin systems
Rege, N. K., Phillips, N. F. B., & Weiss, M. A. (2017) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000345 · Cited by 77
Breaching the Castle Walls: Hyaluronan Depletion as a Therapeutic Approach to Cancer Therapy
Shepard, H. M. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00192 · Cited by 69
Hyaluronan degrading silica nanoparticles for skin cancer therapy
Scodeller, P., Catalano, P. N., Salguero, N., Durán, H., Wolosiuk, A., & Soler‐Illia, G. J. A. A. (2013) · Nanoscale · doi:10.1039/c3nr02787b · Cited by 69
Hyaluronidase-incorporated hyaluronic acid–tyramine hydrogels for the sustained release of trastuzumab
Xu, K., Lee, F., Gao, S., Tan, M., & Kurisawa, M. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.015 · Cited by 70
Hyaluronic acid modified nanostructured lipid carriers for transdermal bupivacaine delivery: In vitro and in vivo anesthesia evaluation
Yue, Y., Zhao, D., & Yin, Q. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.12.103 · Cited by 68
Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open‐label Phase II study
Chari, A., Rodríguez‐Otero, P., McCarthy, H. O., Suzuki, K., Hungria, V., Sureda, A. M., Perrot, A., Hulin, C., Magen, H., Iida, S., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16980 · Cited by 66
Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom
Rule, S., Collins, G. P., & Samanta, K. (2014) · Journal of Medical Economics · doi:10.3111/13696998.2014.914033 · Cited by 66
Cancer immune exclusion: breaking the barricade for a successful immunotherapy
Bruni, S., Mercogliano, M. F., Mauro, F. L., Russo, R. I. C., & Schillaci, R. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1135456 · Cited by 72
Overview of Recombinant Human Hyaluronidase-facilitated Subcutaneous Infusion of IgG in Primary Immunodeficiencies
Wasserman, R. L. (2014) · Immunotherapy · doi:10.2217/imt.14.34 · Cited by 65
Strategies for Glycoengineering Therapeutic Proteins
Dammen‐Brower, K., Epler, P., Zhu, S. E., Bernstein, Z. J., Stabach, P. R., Braddock, D. T., Spangler, J. B., & Yarema, K. J. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.863118 · Cited by 70
Tolerability of High-Volume Subcutaneous Injections of a Viscous Placebo Buffer: A Randomized, Crossover Study in Healthy Subjects
Dias, C., Abosaleem, B., Crispino, C., Gao, B., & Shaywitz, A. (2015) · AAPS PharmSciTech · doi:10.1208/s12249-015-0288-y · Cited by 63
Recombinant Human Hyaluronidase-Enabled Subcutaneous Pediatric Rehydration
Allen, C. H., Etzwiler, L. S., Miller, M. K., Maher, G., Mace, S. E., Hostetler, M. A., Smith, S. R., Reinhardt, N., Hahn, B. J., & Harb, G. (2009) · PEDIATRICS · doi:10.1542/peds.2008-3588 · Cited by 63
Comparative Pharmacokinetics and Insulin Action for Three Rapid-Acting Insulin Analogs Injected Subcutaneously With and Without Hyaluronidase
Morrow, L., Muchmore, D. B., Hompesch, M., Ludington, E. A., & Vaughn, D. E. (2012) · Diabetes Care · doi:10.2337/dc12-0808 · Cited by 60
Measuring Tissue Back-Pressure - In Vivo Injection Forces During Subcutaneous Injection
Allmendinger, A., Mueller, R., Schwarb, E., Chipperfield, M., Huwyler, J., Mahler, H., & Fischer, S. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1611-0 · Cited by 58
Difficult peripheral venous access: recognizing and managing the patient at risk
Walsh, G. (2008) · Journal of the Association for Vascular Access · doi:10.2309/java.13-4-7 · Cited by 58
Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration
Rosengren, S., Dychter, S. S., Printz, M. A., Huang, L., Schiff, R. I., Schwarz, H.-P., McVey, J. K., Drake, F. H., Maneval, D. C., Kennard, D. A., et al. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9782-0 · Cited by 58
Self-citation
Effective targeting of the tumor microenvironment for cancer therapy.
Jiang, P., Li, X., Thompson, C. B., Huang, Z., Araiza, F., Osgood, R. J., Wei, G., Feldmann, M., Frost, G. I., & Shepard, H. M. (2012) · PubMed · Cited by 56
Self-citation
Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency
Wasserman, R. L., Melamed, I., Stein, M. R., Engl, W., Sharkhawy, M., Leibl, H., Puck, J., Rubinstein, A., Kobrynski, L., Gupta, S., et al. (2016) · Journal of Clinical Immunology · doi:10.1007/s10875-016-0298-x · Cited by 52
Safety of recombinant human hyaluronidase PH20 for subcutaneous drug delivery
Knowles, S. P., Printz, M. A., Kang, D. W., LaBarre, M. J., & Tannenbaum, R. P. (2021) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1981286 · Cited by 54
Use of Recombinant Human Hyaluronidase to Accelerate Rapid Insulin Analogue Absorption: Experience with Subcutaneous Injection and Continuous Infusion
Vaughn, D. E., & Muchmore, D. B. (2011) · Endocrine Practice · doi:10.4158/ep11297.ra · Cited by 51
Recombinant Human Hyaluronidase PH20 Does Not Stimulate an Acute Inflammatory Response and Inhibits Lipopolysaccharide-Induced Neutrophil Recruitment in the Air Pouch Model of Inflammation
Huang, Z., Zhao, C., Chen, Y., Cowell, J., Wei, G., Kultti, A. H., Huang, L., Thompson, C. B., Rosengren, S., Frost, G. I., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1303060 · Cited by 52
Self-citation
Clinical evaluation of large volume subcutaneous injection tissue effects, pain, and acceptability in healthy adults
Woodley, W. D., Morel, D. R., Sutter, D. E., Pettis, R. J., & Bolick, N. G. (2021) · Clinical and Translational Science · doi:10.1111/cts.13109 · Cited by 49
Hyaluronidase-powered microneedles for significantly enhanced transdermal delivery efficiency
Hu, W., Peng, T., Huang, Y., Ren, T., Chen, H., Chen, Y., Feng, D., Wu, C., & Pan, X. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.11.046 · Cited by 50
Controlled release of therapeutic antibody formats
Schweizer, D., Serno, T., & Göpferich, A. M. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.08.001 · Cited by 49
Review of the Mechanism of Action and Clinical Efficacy of Recombinant Human Hyaluronidase Coadministration with Current Prandial Insulin Formulations
Muchmore, D. B., & Vaughn, D. E. (2010) · Journal of Diabetes Science and Technology · doi:10.1177/193229681000400223 · Cited by 49
Mechanisms of Subcutaneous Absorption of Rituximab in Rats
Kagan, L., & Mager, D. E. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.048496 · Cited by 49
In Vivo Degradation of Crosslinked Hyaluronic Acid Fillers by Exogenous Hyaluronidases
Shumate, G. T., Chopra, R., Jones, D., Messina, D. J., & Hee, C. K. (2018) · Dermatologic Surgery · doi:10.1097/dss.0000000000001525 · Cited by 49
Subcutaneous delivery of biotherapeutics: challenges at the injection site
Sequeira, J. A. D., Paiva‐Santos, A. C., Serra, J. P., Estevens, C., Seiça, R. M. F., Veiga, F., & Ribeiro, A. J. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1568408 · Cited by 50
Patient-centric design for peptide delivery: Trends in routes of administration and advancement in drug delivery technologies
Ganesh, A. N., Heusser, C., Garad, S., & Sánchez-Félix, M. V. (2020) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2020.100079 · Cited by 49
Emerging hydrogel designs for controlled protein delivery
Bae, K. H., & Kurisawa, M. (2016) · Biomaterials Science · doi:10.1039/c6bm00330c · Cited by 49
FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase–zzxf Injection for Subcutaneous Use in Patients with HER2-positive Breast Cancer
Gao, J. J., Osgood, C. L., Gong, Y. U. T., Zhang, H., Bloomquist, E. W., Jiang, X., Qiu, J., Yu, J., Song, P., Rahman, N. A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3474 · Cited by 47
Strategies for high‐concentration drug substance manufacturing to facilitate subcutaneous administration: A review
Holstein, M. A., Hung, J., Feroz, H. M., Ranjan, S., Du, C., Ghose, S., & Li, Z. J. (2020) · Biotechnology and Bioengineering · doi:10.1002/bit.27510 · Cited by 45
Navigating large-volume subcutaneous injections of biopharmaceuticals: a systematic review of clinical pipelines and approved products
Green, P., Schneider, A., & Lange, J. (2024) · mAbs · doi:10.1080/19420862.2024.2402713 · Cited by 45
Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial
Assouline, S. E., Buccheri, V., Delmer, A. J., Gaïdano, G., Trněný, M., Berthillon, N., Brewster, M., Catalani, O., Li, S., McIntyre, C., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)00004-1 · Cited by 45
Practical considerations in clinical strategy to support the development of injectable drug-device combination products for biologics
Li, Z., & Easton, R. (2017) · mAbs · doi:10.1080/19420862.2017.1392424 · Cited by 45
Innate Immune Cell Suppression and the Link With Secondary Lung Bacterial Pneumonia
Morgan, D. J., Casulli, J., Chew, C., Connolly, E., Lui, S., Brand, O. J., Rahman, R., Jagger, C. P., & Hussell, T. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02943 · Cited by 45
A Phase I Study to Assess the Effect of Speed of Injection on Pain, Tolerability, and Pharmacokinetics After High-volume Subcutaneous Administration of Gantenerumab in Healthy Volunteers
Portron, A., Jordan, P., Draper, K., Muenzer, C., Dickerson, D., van Iersel, T. M., & Hofmann, C. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.11.015 · Cited by 43
Quantitative prediction of therapeutic antibody pharmacokinetics after intravenous and subcutaneous injection in human
Haraya, K., Tachibana, T., & Nezu, J. (2017) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2017.05.002 · Cited by 43
Advanced Formulations/Drug Delivery Systems for Subcutaneous Delivery of Protein-Based Biotherapeutics
Lou, H., Feng, M., & Hageman, M. J. (2022) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2022.08.036 · Cited by 42
Stability of Protein Pharmaceuticals: Recent Advances
Manning, M. C., Holcomb, R. E., Payne, R. W., Stillahn, J. M., Connolly, B. D., Katayama, D. S., Liu, H., Matsuura, J. E., Murphy, B. M., Henry, C. S., et al. (2024) · Pharmaceutical Research · doi:10.1007/s11095-024-03726-x · Cited by 45
Subcutaneous Trastuzumab for HER2-positive Breast Cancer – Evidence and Practical Experience in 7 German Centers
Jackisch, C., Müller, V., Dall, P., Neumeister, R., Park-Simon, T.-W., Ruf-Dördelmann, A., Seiler, S., Tesch, H., & Ataseven, B. (2015) · Geburtshilfe und Frauenheilkunde · doi:10.1055/s-0035-1546172 · Cited by 42
The INFUSE-Morphine Study: Use of Recombinant Human Hyaluronidase (rHuPH20) to Enhance the Absorption of Subcutaneously Administered Morphine in Patients with Advanced Illness
Thomas, J. R., Wallace, M. S., Yocum, R. C., Vaughn, D. E., Haller, M. F., & Flament, J. (2009) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2009.03.009 · Cited by 41
Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia
Assouline, S. E., Buccheri, V., Delmer, A. J., Gaïdano, G., McIntyre, C., Brewster, M., Catalani, O., Hourcade‐Potelleret, F., Sayyed, P. Z., & Badoux, X. C. A. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12662 · Cited by 41
Recombinant Human Hyaluronidase Facilitated Subcutaneous Immunoglobulin Treatment in Pediatric Patients with Primary Immunodeficiencies: Long-Term Efficacy, Safety and Tolerability
Wasserman, R. L., Melamed, I., Kobrynski, L. J., Puck, J. M., Gupta, S., Doralt, J., Sharkhawy, M., Engl, W., Leibl, H., Gelmont, D. M., et al. (2016) · Immunotherapy · doi:10.2217/imt-2016-0066 · Cited by 40
Machine Learning Attempts for Predicting Human Subcutaneous Bioavailability of Monoclonal Antibodies
Lou, H., & Hageman, M. J. (2021) · Pharmaceutical Research · doi:10.1007/s11095-021-03022-y · Cited by 40
Medical resource utilization for administration of trastuzumab in a New Zealand oncology outpatient setting: a time and motion study
Ryan, S., North, R., Harvey, V. J., & Cox, L. (2015) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s85599 · Cited by 41
Current Industry Best Practice on in-use Stability and Compatibility Studies for Biological Products
Blümel, M., Liu, J., de Jong, I., Weiser, S. E., Fast, J. L., Litowski, J. R., Shuman, M., Mehta, S. B., Amery, L., Tan, D. C. T., et al. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.05.002 · Cited by 39
Advancing Subcutaneous Dosing Regimens for Biotherapeutics: Clinical Strategies for Expedited Market Access
Bittner, B., & Schmidt, J. (2023) · BioDrugs · doi:10.1007/s40259-023-00626-1 · Cited by 37
Subcutaneous versus Intravenous Administration of Rituximab: Pharmacokinetics, CD20 Target Coverage and B-Cell Depletion in Cynomolgus Monkeys
Mao, C.-P., Brovarney, M., Dabbagh, K., Birnböck, H., Richter, W., & Nagro, C. J. D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080533 · Cited by 37

Authors: Frost, G. I.
Affiliations: Halozyme Therapeutics (United States) (US)
Corresponding author: Frost, Gregory I
Venue: Expert Opinion on Drug Delivery
Publisher: Informa UK Limited
Published: 2007-07
Volume: 4
Issue: 4
Pages: 427-440
ISSN: 1742-5247 (ISSN-L)
1744-7593
DOI: 10.1517/17425247.4.4.427
OpenAlex: W2158548553
Cited by: 323
References: 66
Citations by year: 2026: 25 · 2025: 18 · 2024: 16 · 2023: 23 · 2022: 15 · 2021: 27 · 2020: 18 · 2019: 8 · 2018: 27 · 2017: 18 · 2016: 19 · 2015: 17 · 2014: 28 · 2013: 12 · 2012: 23
FWCI: 0.45
Type: journal article
Language: en
Open access: closed
Locations: Expert Opinion on Drug Delivery (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Proteoglycans and glycosaminoglycans research
Health Sciences › Medicine › Emergency Medicine › Intramuscular injections and effects
Physical Sciences › Materials Science › Biomaterials › Hydrogels: synthesis, properties, applications
Keywords: recombinant human hyaluronidase, rHuPH20, subcutaneous drug delivery, extracellular matrix, hyaluronic acid, subcutaneous tissue, injection volume, bioavailability, hyaluronidase, glycosaminoglycans, collagen, pharmacokinetics
MeSH terms: Amino Acid Sequence, Animals, Extracellular Matrix, Humans, Hyaluronoglucosaminidase, Injections, Subcutaneous, Molecular Sequence Data, Recombinant Proteins, Solubility, Protein Engineering, Cell Adhesion Molecules, Dermis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks